Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma

Clinical Cancer Research

Volumn 5, Issue 10, 1999, Pages 2756-2765

  Wang, Flora ^a   Bade, Elizabeth ^a   Kuniyoshi, Catherine ^a   Spears, Lucy ^a   Jeffery, Georgia ^a   Marty, Verna ^a   Groshen, Susan ^a   Weber, Jeffrey ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COPOLYMER; CRL 1005; FREUND ADJUVANT; MELANOMA VACCINE; MONTANIDE ISA 51; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; CANCER IMMUNIZATION; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; GRANULOMA; HEADACHE; HIGH RISK POPULATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LIVER TOXICITY; MALE; MELANOMA; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TEST; SUBCUTANEOUS DRUG ADMINISTRATION;

ANTIGENS, NEOPLASM; CANCER VACCINES; CYTOKINES; FEMALE; FREUND'S ADJUVANT; HUMANS; HYPERSENSITIVITY, DELAYED; LYMPHOCYTE ACTIVATION; MALE; MELANOMA; MIDDLE AGED; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION;

EID: 0032724112     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Prehn, R. T., and Main, N. U. Immunity to methylcholanthrene induced sarcomas. J. Natl. Cancer Inst., 18: 769-778, 1957.
2. Kripke, M. L. Antigenicity of murine skin tumors induced by ultraviolet light. J. Natl. Cancer Inst., 53: 1333-1336, 1974.
3. Lurquin, C. A., Van Pel, A., Mariame, B., de Plaen, E., Szikora, J-P., Janssens, C., Reddhase, M. J., Lejeune, J., and Boon, T. Structure of the gene of Tum-transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytotoxic T cells. Cell, 58: 293-303, 1989.
4. Van den Eynde, B., Lehte, B., Van Pel, A., De Plaen, E., and Boon, T. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal sene of synseneic DBA/2 mice. J. Exp. Med., 173: 1373-1384, 1991.
5. Anichini, A., Mazzocchi, A., Fossatti, G., and Parmiani, G. Cytotoxic T lymphocyte clones from peripheral blood and from tumor sites detect intra-tumoral heterogeneity of melanoma cells: analysis of specificity and mechanisms of interaction. J. Immunol., 142: 3692-3701, 1989.
6. Wolfel, T., Klehmann, E., Muller, C., Schutt, K. H., Meyer zum Buschenfelde, K. H., and Knuth, A. Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leucocyte antigen A2 as a restriction element for three different antigens. J. Exp. Med., 170: 797-810, 1989.
7. Topalian, S. L., Solomon, D., and Rosenberg, S. A. Tumor specific cytolysis by lymphocytes infiltrating human tumors. J. Immunol., 142: 3714-3725, 1989.
8. Traversari, C., van der Bruggen, P., Luescher, I., Lurquin, C., Chomey P., Van Pel, A., De Plaen, E., Amar-Costesec, A., and Boon, T. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med., 176: 1453-1457, 1992.
9. Gaugler, B., van den Eynde, B., van der Bruggen, P., Romero, P., Gaforio, J. J., De Plaen, E., Lethe, B., Brasseur, F., and Boon, T. Human gene MAGE-3 codes for an antigen recognized on melanoma cells by autologous lymphocytes J. Exp. Med., 179: 921-930, 1994.
10. Kawakami, Y., Eliyahu, S., Delgado, C., Robbins, P. F., Rivoltini, L., Yanelli, J. R., Appella, E., and Rosenberg, S. A. Cloning of the gene coding for a shared melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA, 96: 3515-3519, 1994.
11. Coulie, P. G., Brichard, V., Van Pel, A., Wolfel, T., Schneider, J., Traversari, C., Mattei, S., De Plaen, E., Lurquin, C., Szikora, J. P., and Boon, T. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med., 180: 35-42, 1994.
12. Bakker, A. B. H., Schreurs, W. J., de Boer, A. J., Kawakami, Y., Rosenberg, S. A., Adema, G. J., and Figdor, C. G. Melanocyte lineage specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med., 779: 1005-1009, 1994.
13. Kawakami, Y., Eliyahu, S., Delgado, C., et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA. 91: 6458-6462, 1994.
14. Brichard, V., Van Pel, A., Wolfel, T., et al. The tyrosinase gene encodes for an antigen recosnized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med., 178: 489-495, 1993.
15. Wang, R. F., Robbins, P. F., Kawakami, Y., et al. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31 restricted tumor-infiltrating lymphocytes. J. Exp. Med., 181: 799-806, 1995.
16. Wang, R-F., Parkhurst, M. R., Kawakami, Y., Robbins, P. F., et al. Utilization of an alternative open reading frame of a normal gene in generating a human cancer antigen. J. Exp. Med., 183: 1131-1138, 1996.
17. Wang, R-F., Appella, E., Kawakami, Y. Kang, X., and Rosenberg, S. A. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J. Exp. Med., 184: 2207-2214, 1996.
18. Jaeger, E., Chen, Y-T., Drijfhout, J. W., Karbach, J., Ringhaffer, M., Jager, D., Arand, M., Wada, H. Noguchi, Y., Stuckert, E., Old, L. J., and Knuth, A. Simultaneous humoral and cellular immune response against cancer testis antigen NY-ESO-1: definition of human histocompatibility leucocyte antigen (HLA)-A2 binding peptide epitopes. J. Exp. Med., 187: 265-274, 1998.
19. Wolfel, C, Klehman-Hieb, E., De Plaen, E., Hankeln, T., Meyer zum Buschenfelde, K. H., and Beach, D. A p16INK4a-insensitive CDK4 mutant targeted by cytotoxic T lymphocytes in a human melanoma. Science (Washington DC), 269: 1281-1285, 1995.
20. Robbins, P. F., El-Gamil, M., Li, Y. F., Kawakami, Y., Loftus, D., Appella, E., and Rosenberg, S. A. A mutated β-catenin gene encodes a melanoma specific antigen recognized by tumor-infiltrating lymphocytes. J. Exp. Med., 183: 1185-1192, 1996.
21. Townsend, A. R. M., Gotch, R. M., and Davey, J. Cytotoxic cells recognize fragments of the influenza nucleoprotein. Cell, 42: 457-467, 1985.
22. Townsend, A. R. M., Rothbard, J., Gotch, F. M., Bahadur, G., Wraith, P., and McNechael, A. J. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell, 44: 959-968, 1986.
23. Maryanski, J. L., Paola, P., Coradin, G., Jordan, B. R., and Cerottini, J. C. H2-restricted cytotoxic T cells specific for HLA can recognize a synthetic HLA peptide. Nature (Lond.), 324: 578-579, 1986.
24. Hill, A., and Ploegh, H. Getting the inside out: the transporter associated with antigen processing (TAP) and the presentation of viral antigen. Proc. Natl. Acad. Sci. USA. 92: 341-343, 1995.
25. Falk, K., Rotzschke, S., Stepanovic, S., Tung, G., and Rammensel, H. G. Alelle specific motifs revealed by sequencing of self peptides eluted from MHC molecules. Nature (Lond.), 351: 290-293, 1991.
26. Rupert, J., Sidney, J., Celis, E., Kubo, R. T., Grey, H. M., and Sette, A. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell, 74: 929-936, 1993.
27. Kubo, R. T., Sette, A., Grey, H. M., Apella, E., Sakaguchi, K., Zhu, N. Z., Arnott, D., Sherman, N., Shabonowitz, J., and Michel, H. Definition of specific peptide motifs for four major HLA-A alleles. J. Immunol., 752: 3913-3919, 1994.
28. Celis, E., Tsai, V., DeMars, R., Wentworth, P. A., Chestnut, R. W., Grey, H., Sette, A., and Serra, H. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc. Natl. Acad. Sci. USA, 91: 2105-2109, 1994.
29. Boon, T., and Van Der Bruggen, P. Human tumor antigens recognized by T lymphocytes J. Exp. Med., 183: 1173-1176, 1996.
30. Kawakami, Y., Zakut, R., Topalian, S. L., Stetter H., and Rosenberg, S. A. Shared human melanoma antigens: recognition by tumor-infiltrating lymphocytes in HLA-A2.1 transfected melanomas. J. Immunol., 148: 638-643, 1992.
31. Anichini, A., Maccalli, C. Mortarini, R., Salvi, S., Mazzocchi, A., Squarcina, P., Herlyn, M., and Rosenberg, S. A. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2 restricted cytotoxic T cell clones from melanoma patients. J. Exp. Med., 177: 989-997, 1993.
32. Darrow, T. L., Singluff, C. L., and Seigler, H. A. The role of HLA class I antigens in recognition of melanoma cells by tumor specific cytotoxic T lymphocytes. Evidence for shared tumor antigens. J. Immunol., 142: 3329-3335, 1989.
33. Kawakami, Y., Eliyahu, S., Delgado, C., Robbins, P. F., Rivoltini, L., Topalian, S., Miki, T., and Rosenberg, S. A. Cloning of the gene coding for a shared melanoma antigen recognized by autoloaous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA, 91: 3515-3519, 1994.
34. Kawakami, Y., Eliyahu, S., Sakaguchi, K., Robbins, P. F., Rivoltini, L., Yanelli, J. R., Appella, E., and Rosenberg, S. A. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med., 180: 347-352, 1994.
35. Stevens, E., Jacknin, L., Robbins, P. F., Kawakami, Y., el Gamil, M., Rosenberg, S. A., and Yanelli, J. R. The generation of tumor specific cytotoxic lymphocytes from melanoma patients using peripheral blood stimulated with allogeneic melanoma tumor cell lines: fine specificity and MART-1 melanoma antigen recognition. J. Immunol., 754: 762-767, 1995.
36. Rivoltini, L., Kawakami, Y., Sakaguchi, K., Southwood, S., Sette, A., Robbins, P. F., Marinola, F. M., Salgaller, M. L., Yanelli, J. R., Appella, E., and Rosenberg, S. A. Induction of tumor reactive CTL from peripheral blood, and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J. Immunol., 154: 2257-2265, 1995.
37. Cole, D. J., Weil, D. P., Shilyansky, J., Custer, M., Kawakami, Y., Rosenberg, S. A., and Nishimura, M. Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1 melanoma tumor antigen. Cancer Res., 55: 748-752, 1995.
38. Salvi, S., Segalla, F., Rao, S., Arenti, F., Sartor, M., Bratina, G., Caronni, E., Anichini, A., Clemente, C., and Parmiani, G. Overexpression of the T-cell receptor β-chain variable region TCRBV14 in HLA-A2 matched primary human melanoma. Cancer Res., 55: 3374-3379, 1995.
39. Sensi, M., Salvi, S., Castelli, C., Maccalli, C., Mazzocchi, A., Mortarine, R., Nicolini, G., Herlyn, M., Parmiani, G., and Anichini, A. T cell receptor structure of autologous melanoma reactive cytotoxic T lymphocyte (CTL) clones: tumor infiltrating lymphocytes overexpress in vivo the TCR (3 chain sequence used by an HLA-A2 restricted and melanocyte lineage-specific CTL clone J. Exp. Med., 178: 1231-1248, 1993.
40. Hunt, D. F., Henderson, R. A., Shabanowitz, J., Sakaguchi, K., Michel, H., Sevilin, N., Cox, A. L., Appella, E., and Englehard, U. H. Characterization of peptides bound to the class I molecule HLA-A2.1 by mass spectromelry. Science (Washington DC), 255: 1261-1264, 1992.
41. Storkus, W. J., Zeh, H. J., Maeurer, M. J., Salter, R. D., and Lotze, M. T. Identification of human melanoma peptides recognized by class I restricted tumor infiltrating lymphocytes. J. Immunol., 151: 3719-3726, 1993.
42. Cox, A. L., Skipper, J., Chen, Y., Henderson, R. A., Darrow, T. L., Shabonowitz, J., Engelhard, U. L., Hunt, D. F., and Slingluff, C. L. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science (Washington DC), 264: 716-719, 1994.
43. Loftus, D. J., Castelli, C., Clay, T. M., Squarcina, P., Marincola, F. M., Nishimura, M. I., Parmiani, G., Appella, E., and Rivoltini, L. Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35). J. Exp. Med., 184: 647-657, 1996.
44. Marincola, F. M., Rivoltini, L., Salgaller, C. C., Player, M., and Rosenberg, S. A. Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells. J. Immunother., 19: 266-277, 1996.
45. Cormier, J. N., Salgaller, C. C., Prevette, T., Barracchini, K. C., Rivoltini, L., Restifo, N. P., Rosenberg, S. A., and Marincola, F. M. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J. Sci. Am., 3: 37-44, 1997.
46. Jager, E., Ringhoofer, M., Karbac, J., Jager, D., Ilsemann, C., Hagedorn, M., Oesch, F., and Knuth, A. Inverse relationship of melanoma differentiation antigen expression in melanoma tissues and CD8+ cytotoxic T cell responses: evidence for immunoselection of antigen loss variants in vivo. Int. J. Cancer, 66: 470-476, 1996.
47. Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., and Schadendorf, D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med., 4: 378-332, 1998.
48. Romero, P., Gervois, N., Schneider, J., Escobar, P., Valmori, D., Pannetier, C., Steinle, A., Wolfel, T., Lienard, D., Brichard, V., van Pel, A., Jotereau, F., and Cerottini, J. C. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma. J. Immunol., 759: 2366-2374, 1997.
49. Valmori, D., Fonteneau, J. F., Lizana, C. M., Gervois, N., Lienard, D., Rimoldi, D., Jongeneel, V., Jotereau, F., Cerottini, J. C., and Romero, P. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J. Immunol., 160: 1750-1758, 1998.
50. Fleischhauer, K., Tanzarella, S., Wallny, H. J., Bordignon, C., and Traversari, C. Multiple HLA-A alleles can present an immunodominant peptide of the human melanoma antigen Melan-A/MART-1 to a peptide-specific HLA-A*0201+ cytotoxic T cell line. J. Immunol., 157: 787-797, 1996.
51. Rivoltini, L., Loftus, D. J., Barracchini, K., Arienti, F., Mazzocchi, A., Biddison, W. E., Salgaller, C. C., Appella, E., Parmiani, G., and Marincola, F. M. Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy. J. Immunol., 156: 3882-3891, 1996.
52. Schneider, J., Brichard, V., Boon, T., Meyer zum Buschenfelde, K. H., and Wolfel, T. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.I. Int. J. Cancer, 75: 451-458, 1998.
53. Marincola, F. M. Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy. J. Immunol., 161: 877-889, 1998.
54. Chen, Y. T., Stockert, E., Jungbluth, A., Tsang, S., Coplan, K. A., Scanlan, M. J., and Old, L. J. Serological analysis of Melan-A (MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas. Proc. Natl. Acad. Sci. USA, 93: 5915-5919, 1996.
55. Fetsch, P. A., Cormier, J., Hijazi, Y. M. Immunocytochemical detection of MART-1 in fresh and paraffin-embedded malignant melanomas. J. Immunother., 20: 60-64, 1997.
56. Marincola, F. M., Hijazi, Y. M., Fetsch, P., Salgaller, C. C., Rivoltini, L., Cormier, J., Simonis, T. B., Duray, P. H., Herlyn, M., Kawakami, Y., and Rosenberg, S. A. Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions. J. Immunother., 19: 192-205, 1996.
57. Kageshita, T., Kawakami, Y., Hirai, S., and Ono, T. Differential expression of MART-1 in primary and metastatic melanoma lesions. J. Immunother., 20: 460-465, 1997.
58. de Vries, T. J., Fourkour, A., Wobbes, T., Verkroost, G., Ruiter, D. J., and van Muijen, G. N. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Res., 57: 3223-3229, 1997.
59. Dalerba, P., Ricci, A., Russo, V., Rigatti, D., Nicotra, M. R., Mottolese, M., Bordignon, C., Natali, P. G., and Traversari, C. High homogeneity of MAGE, BAGE, GAGE, tyrosinase and Melan-A/MART-1 gene expression in clusters of multiple simultaneous metastases of human melanoma: implications for protocol design of therapeutic antigen-specific vaccination strategies. Int. J. Cancer, 77: 200-204, 1998.
60. Cormier, J. N., Abati, A., Fetsch, P., Hijazi, Y. M., Rosenberg, S. A., Marincola, F. M., and Topalian, S. L. Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy. J. Immunother., 21: 27-31, 1998.
61. Maeurer, M. J., Gollin, S. M., Martin, D., Swaney, W., Bryant, J., Castelli, C., Robbins, P., Parmiani, G., Storkus, W. J., and Lotze, M. T. Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J. Clin. Investig., 98: 1633-1641, 1996.
62. van Elsas, A., van der Burg, S. H., van der Minne, C. E., Borghi, M., Mourer, J. S., Melief, C. J., and Schrier, P. I. Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/ MART-1 self antigen. Eur. J. Immunol., 26: 1683-1689, 1996.
63. Rosenberg, S. A., and White, D. E. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J. Immunother., 19: 81-84, 1996.
64. Kim, C. J., Prevette, T., Cormier, J., Overwijk, W., Roden, M., Restifo, N. P., Rosenberg, S. A., and Marincola, F. M. Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro. J. Immunother., 20: 276-286, 1997.
65. Ribas, A., Butterfield, L. H., McBride, W. H., Jilani, S. M., Bui, L. A., Vollmer, C. M., Lau, R., Dissette, V. B., Hu, B., Chen, A. Y., Glaspy, J. A., and Economou, J. S. Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells. Cancer Res., 57: 2865-2869, 1997.